- Home
- SKYE vs FNGR Comparison
SKYE vs FNGR Comparison
Compare SKYE & FNGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- FNGR
- Stock Information
- Founded
- SKYE 2012
- FNGR 2016
- Country
- SKYE United States
- FNGR Singapore
- Employees
- SKYE N/A
- FNGR N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- FNGR Computer Software: Prepackaged Software
- Sector
- SKYE Health Care
- FNGR Technology
- Exchange
- SKYE Nasdaq
- FNGR Nasdaq
- Market Cap
- SKYE 94.0M
- FNGR 68.3M
- IPO Year
- SKYE N/A
- FNGR N/A
- Fundamental
- Price
- SKYE $2.73
- FNGR $1.13
- Analyst Decision
- SKYE Buy
- FNGR
- Analyst Count
- SKYE 6
- FNGR 0
- Target Price
- SKYE $18.67
- FNGR N/A
- AVG Volume (30 Days)
- SKYE 167.7K
- FNGR 580.4K
- Earning Date
- SKYE 02-09-2025
- FNGR 01-21-2025
- Dividend Yield
- SKYE N/A
- FNGR N/A
- EPS Growth
- SKYE N/A
- FNGR N/A
- EPS
- SKYE N/A
- FNGR N/A
- Revenue
- SKYE N/A
- FNGR $31,176,174.00
- Revenue This Year
- SKYE N/A
- FNGR $260.03
- Revenue Next Year
- SKYE N/A
- FNGR N/A
- P/E Ratio
- SKYE N/A
- FNGR N/A
- Revenue Growth
- SKYE N/A
- FNGR N/A
- 52 Week Low
- SKYE $2.25
- FNGR $1.03
- 52 Week High
- SKYE $19.41
- FNGR $3.96
- Technical
- Relative Strength Index (RSI)
- SKYE 37.40
- FNGR 31.64
- Support Level
- SKYE $2.31
- FNGR $1.10
- Resistance Level
- SKYE $3.04
- FNGR $1.27
- Average True Range (ATR)
- SKYE 0.30
- FNGR 0.10
- MACD
- SKYE 0.07
- FNGR -0.00
- Stochastic Oscillator
- SKYE 44.68
- FNGR 20.00
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About FNGR FingerMotion Inc.
FingerMotion Inc is engaged in the provision of mobile payment and recharge services in the Chinese market. The company business line includes Telecommunications Products and Services; Value Added Products and Services; Short Message Services (SMS) and Multimedia Messaging Services (MMS); a Rich Communication Services (RCS) platform; Big Data Insights; and a Video Games Division (inactive). It principally earns revenue by providing mobile payment and recharge services to customers of telecommunications companies in China.